On March 23, 2026, Abbott Laboratories announced the successful completion of its acquisition of Exact Sciences Corporation, a significant move that positions Abbott as a leader in the rapidly growing cancer screening and diagnostics market. The acquisition was executed through a merger agreement dated November 19, 2025, where Abbott's wholly owned subsidiary, Badger Merger Sub I, Inc., merged with Exact Sciences, resulting in Exact becoming a wholly owned subsidiary of Abbott.

As part of the merger, each share of Exact Sciences' common stock was converted into the right to receive $105.00 in cash, excluding any applicable withholding taxes. This strategic acquisition not only enhances Abbott's portfolio but also aligns with its mission to improve healthcare accessibility and empower individuals in managing their health.

Abbott's CEO, Robert B. Ford, emphasized the company's commitment to expanding access to essential tools for early cancer detection and personalized treatments, leveraging Abbott's global scale and operational excellence. The merger is expected to significantly enhance Abbott's capabilities in the cancer diagnostics sector, which is projected to grow substantially as global cancer incidence continues to rise.

The acquisition of Exact Sciences adds a new growth vertical to Abbott's existing operations, which already anticipates high-single-digit growth. This move is expected to solidify Abbott's leadership in the $60 billion U.S. cancer screening and precision oncology diagnostics market, further advancing its strategic objectives in the healthcare sector.

The completion of this acquisition marks a pivotal moment for Abbott, as it seeks to transform cancer care and improve patient outcomes through innovative diagnostic solutions. The last trading day for Exact Sciences shares on the Nasdaq was March 20, 2026, prior to the merger's effective date.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.